Farnesyltransferase inhibitors: mechanism and applications (Q34481874)

2 August 2017

1 reference

title

Farnesyltransferase inhibitors: mechanism and applications (English)

1 reference

2 August 2017

Prendergast GC

1

1 reference

PubMed ID

11772308

2 August 2017

Rane N

series ordinal

2

1 reference

PubMed ID

11772308

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

12

1 reference

2 August 2017

2105-2116

1 reference

Mechanism-based target identification and drug discovery in cancer research

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Biological effects and mechanism of action of farnesyl transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Regulators and Effectors of ras Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Function and regulation of ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Essential role for oncogenic Ras in tumour maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Altered growth of human colon cancer cell lines disrupted at activated Ki-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Protein prenyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Actin' up: RhoB in cancer and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Genomic analysis of metastasis reveals an essential role for RhoC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Transcriptional activation of the small GTPase gene rhoB by genotoxic stress is regulated via a CCAAT element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Rho GTPases are over-expressed in human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

An essential part for Rho-associated kinase in the transcellular invasion of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.12.2105

10.1517/13543784.10.12.2105

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11772308